News | January 28, 2023
Aarti Drugs Q3 FY23 revenue grows 4%
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Cell sorting technology supports researchers advancing new therapies
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
The company has played an important role in the procurement and distribution of emergency medical supplies supporting the Union Health Ministry for Covid–19 pandemic management
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
The objective of this system is to shift the focus of measuring performance of hospitals from volume of services provided to value of healthcare services
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
Miravo to remain a Canadian controlled and operated company following closing of the transaction
Subscribe To Our Newsletter & Stay Updated
